Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Nothing about Evomela per say but some background on what pts have to deal with when being treated for Multiple Myeloma with ASCT. From a NEJM article titled “Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma”

During the past decade, high-dose chemotherapy with autologous stem-cell transplantation has become the standard treatment for newly diagnosed myeloma in patients younger than 65 years of age. However, the median duration of response after this procedure does not exceed 3 years, and few patients remain free of the disease for more than 10 years.1-4

Relapses are due to the failure of high-dose chemotherapy to eradicate all myeloma cells. Maintenance treatments have been proposed to control the proliferation of residual malignant cells after transplantation. For many years, interferon with or without glucocorticoids was used,1,2,5 but this approach was abandoned because of the toxicity of interferon and the negative results of a large, randomized trial.6 Thalidomide has renewed the interest in maintenance therapy after transplantation. In randomized trials, thalidomide was reported to improve rates of event-free or overall survival7-11; however, the long-term use of thalidomide was associated with a high incidence of severe neuropathy. Furthermore, there is no consensus about the benefit of thalidomide for patients with an adverse cytogenetic profile at the time of diagnosis or for those who have already had a complete response after transplantation.7,8,11 Thus, effective maintenance treatment after transplantation is still needed…
http://www.nejm.org/doi/full/10.1056/NEJMoa1114138